It was a busy week for the Contemporary OB/GYN® team.
This week's top articles included:
As parts of the United States enact tough anti-abortion legislation, Mexico’s Supreme Court sets its own precedent.
The official declaration means more funding for research initiatives.
Associate Editor Lindsey Carr sat down with Gary Schoolnik, MD, Visby Medical’s Chief Medical Officer, to learn more about the device’s functionality and application.
Results of a phase 2 study demonstrate that the anti-programmed death-1 (PD-1) antibody balstilimab from Agenus Inc. provides meaningful and durable clinical activity in patients with previously treated, recurrent/metastatic cervical cancer.
Michael Krychman, MD discusses his perspective as a physician during the second wave of COVID-19, and shares some insight into ways other health care professionals can cope.
FDA grants 510(k) clearance to chemiluminescence-based immunoassay
Published: January 10th 2025 | Updated: January 10th 2025The automated chemiluminescence-based immunoassay has received clearance for free testosterone, providing enhanced diagnostic options to a multitude of conditions.
Read More